Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Real-world outcomes of everolimus-based therapy after CDK4/6 inhibitor therapy in ER-positive/HER2-negative metastatic breast cancer: a multicenter registry-based study.

BACKGROUND Everolimus-based endocrine therapy is used for estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER-positive/HER2-negative) metastatic breast cancer after cyclin-dependent kinase 4/6 (CDK4/6) inhibitor treatment, but factors associated with treatment durability remain unclear. We...

Hikari Kiyohara, Toru Hanamura, Y. Sagara et al. · 0 citations
Oct 2026

Tumor Immune Microenvironment and VAF-inferred BRCA1/2 Loss of Heterozygosity in Japanese Patients With Germline BRCA1/2-mutated Breast Cancer

Background/Aim: Germline BRCA1/2 mutations (gBRCA1/2m) confer a markedly increased lifetime risk of breast cancer. Although diverse second-hit mechanisms lead to biallelic inactivation of BRCA1/2, their relationship with the immune microenvironment remains poorly understood, particularly in Japanese populations. Patien...

Yukino Kawamura, K. Mori, F. Takeuchi et al. · 0 citations
Open access Aug 2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

BACKGROUND The randomised phase III OlympiA trial (NCT02032823) compared 1 year of adjuvant olaparib (oral poly-(ADP-ribose) polymerase [PARP] inhibitor) to placebo in 1,836 patients with pathogenic/likely pathogenic BRCA1 or BRCA2 (gBRCApv) germline variants and high-risk human epidermal growth factor receptor 2 (HER2...

J. Garber, D. Cameron, C. Campbell et al. · 1 citation
Review Aug 2026

De-escalation of perioperative systemic therapy for early breast cancer.

Current evidence and ongoing studies on treatment de-escalation across breast cancer subtypes are summarized and integration of molecular biomarkers with response-adapted strategies may further refine risk stratification and support personalized treatment approaches.

M. Ono, Y. Sagara, Toshiyuki Ishiba et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.